(CLOI) VanEck Trust - VanEck CLO - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US92189H7483
CLOI: CLO Tranches, Ultrashort Bonds, Foreign Currency Bonds
The VanEck CLO ETF is an actively managed fund that focuses on investment-grade debt tranches of collateralized loan obligations (CLOs), with a primary emphasis on U.S. dollar-denominated securities. While it maintains a flexible investment strategy, allowing for up to 30% of its net assets to be invested in foreign currency-denominated CLOs, its core objective is to capitalize on the yield and diversification benefits offered by the CLO market.
As a non-diversified ETF, the funds investment approach is centered around the Advisors expertise in selecting CLO securities that meet specific criteria, potentially leading to a concentrated portfolio. The CLO market, being a significant segment of the structured finance universe, offers exposure to a diversified pool of corporate loans, typically with a floating rate feature that can provide a natural hedge against interest rate fluctuations.
Given the current market conditions and the technical indicators, such as the Last Price being above both the SMA20 and SMA50, and the proximity to the 52W High, it suggests a positive short-term outlook. The ATR indicates a relatively low volatility, which could be favorable for investors seeking stable returns. Combining these technical signals with the fundamental aspect of the funds substantial AUM ($1039.32M USD), which indicates a certain level of investor confidence and liquidity, we can forecast a potential short-term stability or slight appreciation in the funds price.
Forecasting further, if the SMA20 and SMA50 continue to support the current price level, and given the funds investment in high-grade CLO tranches, we might see CLOI maintaining its value or slightly increasing, potentially testing its 52W High. However, any significant deviation from the current technical setup or adverse changes in the CLO market could alter this trajectory. Investors should closely monitor the Advisors investment decisions and overall market conditions to adjust their strategies accordingly.
Additional Sources for CLOI ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
CLOI ETF Overview
Market Cap in USD | 1,036m |
Category | Ultrashort Bond |
TER | 0.40% |
IPO / Inception | 2022-06-21 |
CLOI ETF Ratings
Growth Rating | 44.4 |
Fundamental | - |
Dividend Rating | 76.9 |
Rel. Strength | 10.4 |
Analysts | - |
Fair Price Momentum | 55.83 USD |
Fair Price DCF | - |
CLOI Dividends
Dividend Yield 12m | 6.35% |
Yield on Cost 5y | 7.78% |
Annual Growth 5y | 46.42% |
Payout Consistency | 100.0% |
Payout Ratio | % |
CLOI Growth Ratios
Growth Correlation 3m | 91.9% |
Growth Correlation 12m | 96.6% |
Growth Correlation 5y | 99.6% |
CAGR 5y | 7.56% |
CAGR/Max DD 5y | 0.00 |
Sharpe Ratio 12m | 0.19 |
Alpha | 1.22 |
Beta | 0.129 |
Volatility | 1.65% |
Current Volume | 62.4k |
Average Volume 20d | 199.3k |
As of June 25, 2025, the stock is trading at USD 53.00 with a total of 62,389 shares traded.
Over the past week, the price has changed by +0.21%, over one month by +0.59%, over three months by +1.87% and over the past year by +6.58%.
Partly, yes. Based on ValueRay´s Analyses, VanEck Trust - VanEck CLO (NYSE ARCA:CLOI) is currently (June 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 44.38 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLOI is around 55.83 USD . This means that CLOI is currently overvalued and has a potential downside of 5.34%.
VanEck Trust - VanEck CLO has no consensus analysts rating.
According to our own proprietary Forecast Model, CLOI VanEck Trust - VanEck CLO will be worth about 60.4 in June 2026. The stock is currently trading at 53.00. This means that the stock has a potential upside of +14.04%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 60.4 | 14% |